Leukocytoclastic Vasculitis Drug Reaction to Certolizumab Pegol

Woody, Meghan; Warren, Donald W.; Speck, Laura; Jackson, Julie

doi:10.1080/08998280.2017.11929591

Cited by 6 publications

(4 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar to our patients, LCV cases associated with various biologic agents were reported to have TNF-α inhibitor treatment previously which was switched due to inefficiency. 4,7,9 Therefore, we believe that previous administration of TNF-α inhibitors may possibly be considered as a risk factor to develop LCV under subsequent biologic agent administration. The use of TNF-α inhibitors might have resulted in antidrug antibody formation which can contribute to LCV development.…”

mentioning

confidence: 99%

Vasculitis during certolizumab pegol and secukinumab treatment: Report of two cases

Bostan

Gülseren

Yalıcı-Armağan

et al. 2021

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

Vasculitis during certolizumab pegol and secukinumab treatment: Report of two cases

Bostan

Gülseren

Yalıcı-Armağan

et al. 2021

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“…27 A case of CZP-associated leukocytoclastic vasculitis was also reported. 28 In another study evaluating TA patients treated with TNF inhibitors, 33% of patients experienced disease relapse and 55% discontinued treatment because of relapse, persistently active disease, lack of corticosteroid-sparing effect, adverse effects or other reasons. 29 In our report, one out of the three patients was refractory to CZP, in accordance with the literature.…”

Section: Discussionmentioning

confidence: 99%

Certolizumab Pegol Treatment in Three Patients With Takayasu Arteritis

et al. 2019

View full text Add to dashboard Cite

Takayasu arteritis (TA) is a rare granulomatous large vessel vasculitis which primarily affects aorta and its major branches. TA can result in stenosis, occlusion, aneurysm formation, and dilatation of effected vessels. 1 Females are predominantly affected with an age of onset of ≤40 years. 2 Although its distribution is worldwide, it generally affects Asian populations. TA is relatively uncommon in northern European and American populations. 3 Although the etiology of TA is unknown, cell-mediated autoimmunity and genetic factors have an important role in the pathogenesis of TA. 4 Clinical manifestations are determined by the affected vessels and degree of inflammation. 5 TA generally progresses through three different phases. In the first prevasculitic phase, patients complain of nonspecific constitutional symptoms such as fever, fatigue, and malaise. In the second inflammatory phase, vascular pain (particularly carotidynia) tends to occur. The third burnedout phase is characterized with arterial bruits, decreased or absence of pulses and/or differences in arterial blood pressure between upper extremities, claudication in the legs and ischemic symptoms. 6 An overlap may be observed between these phases. There is no gold standard laboratory test and imaging method for diagnosis of TA. The American College of Rheumatology (ACR) criteria are the most widely used vasculitis classification criteria. 7 The main target of treatment in TA is to suppress the inflammatory process. Management of cardiovascular risk factors such as dyslipidemia, smoking, and hypertension is also important. Corticosteroids (CS) are the mainstay of therapy. Methotrexate (MTX), azathioprine (AZA), cyclosporine, tacrolimus, mycophenolate mofetil,

show abstract

“…Our literature search found only one case of HUV development during TNF‐α–blocking agent treatment, which involved psoriatic arthritis treatment with ETN . Moreover, Woody et al reported the case of a patient receiving CZP treatment for LCV . However, they did not provide serological details, such as serum complement levels upon LCV development, under the influence of CZP.…”

Section: Case Descriptionmentioning

confidence: 96%

“…Although TNF‐α–blocking agents, such as infliximab and ETN, that were approved earlier than CZP were found to be associated with the occurrence of LCV, a link between LCV and CZP had been rarely reported . Currently, only one case of LCV during CZP treatment has been reported by Woody et al in a patient with Crohn's disease and ankylosing spondylitis . Given that CZP is univalent, it is presumed to abstain from forming large immune complexes, such as those formed by other bivalent TNF‐α–blocking agents .…”

Section: Case Descriptionmentioning

confidence: 99%

Development of hypocomplementemic urticarial vasculitis during certolizumab pegol treatment for rheumatoid arthritis: A case report

et al. 2020

View full text Add to dashboard Cite

What is known and objective Tumour necrosis factor‐α–blocking agents potentially cause vasculitis. However, no study has reported on the association between hypocomplementemic urticarial vasculitis (HUV) and certolizumab pegol (CZP) usage. Case description We present the first case of HUV development during CZP treatment for rheumatoid arthritis. Hypocomplementemic urticarial vasculitis improved after CZP was discontinued and the dose of oral prednisolone was increased. What is new and conclusion Clinicians should be aware about the potential development of HUV during CZP treatment, which is presumed to be safe considering its unique structural characteristics that differ from those of other tumour necrosis factor‐α–blocking agents.

show abstract

Leukocytoclastic Vasculitis Drug Reaction to Certolizumab Pegol

Cited by 6 publications

References 11 publications

Vasculitis during certolizumab pegol and secukinumab treatment: Report of two cases

Vasculitis during certolizumab pegol and secukinumab treatment: Report of two cases

Certolizumab Pegol Treatment in Three Patients With Takayasu Arteritis

Development of hypocomplementemic urticarial vasculitis during certolizumab pegol treatment for rheumatoid arthritis: A case report

Contact Info

Product

Resources

About